Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;20(3):313-318.
doi: 10.7861/clinmed.2019-0250.

Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment

Ahmed Hussain  1 , Preya J Patel  1 , Freya Rhodes  1 , Ankur Srivastava  1 , David Patch  1 , William Rosenberg  2
Affiliations

Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment

Ahmed Hussain et al. Clin Med (Lond). 2020 May.

Abstract

Non-alcoholic fatty liver disease (NAFLD) accounts for 10-15% of orthotopic liver transplants (OLTs) in the UK. Index presentations with cirrhotic decompensation represent missed opportunities for preventive treatment leaving OLT or palliation as the only options.We retrospectively reviewed patient records for all NAFLD patients undergoing assessment for OLT between January 2003 and December 2017.Data were available for 81 patients with NAFLD as the primary diagnosis. Fifty-two patients had decompensated cirrhosis at first presentation; 91.7% presented to secondary care compared to 52.7% referred from primary care (p=0.001). Cirrhosis was not suspected at the time of referral to hospital in 24.7% of patients subsequently assessed for OLT. Most patients undergoing assessment for OLT for NAFLD had decompensated cirrhosis at their first diagnosis of chronic liver disease. These data highlight the plight of patients with NAFLD cirrhosis in whom chronic liver disease is diagnosed late.

Keywords: Non-alcoholic fatty liver disease; cirrhosis; decompensation; prognosis; transplantation.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Proportions of patients presenting to healthcare with decompensated disease.
Fig 2.
Fig 2.
Outcomes of transplant assessment.
Fig 3.
Fig 3.
Survival curve analysis for patients who underwent orthotopic liver transplant.
See this image and copyright information in PMC

References

    1. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol 2014;5:277–86. - PMC - PubMed
    1. Glen J, Floros L, Day C, et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ 2016;354:i4428. - PubMed
    1. Lonardo A, Sookoian S, Pirola CJ, et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2016;65:1136–50. - PubMed
    1. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–54. - PubMed
    1. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874–82. - PubMed